Castle Biosciences Inc (CSTL): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Brandmark of Castle Biosciences Corp (CSTL)

Despite a shortage of reagents driven by geopolitics, Castle Biosciences is actively expanding its list of tests for insurance coverage. The company's EV/EBITDA multiple chart visualizes current market value relative to earnings, where the value 0.00 shows the current figure. High diagnostic accuracy is achieved through laboratory robotization and the implementation of AI, which completely eliminates human error.

Castle Biosciences Corp - CSTL EV/EBITDA Multiple (period 11/23/2025 - 11/10/2026)

CSTL (castlebiosciences.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Castle Biosciences Corp|CSTL - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Castle Bio|CSTL - Business Value
- book value of equity indicators:
Book Value per Share Castle Biosciences|CSTL - Book Capitalization|Market Value to Book Value Ratio castlebiosciences.com|CSTL - Aggregate Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Castle Biosciences|CSTL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Castle Biosciences, Inc.|CSTL - Company Total Debt Obligations|Debts to Book Capitalization Castle Bio|CSTL - Long-Term Debt Volume|Company Short-Term Debt Castle Biosciences|Quick Ratio castlebiosciences.com
- financial results and valuation multiples details:
CSTL - Net Income|Projected Future Earnings Castle Biosciences|CSTL - P/E Multiple|Future Price to Earnings Castle Biosciences|CSTL - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Castle Bio|CSTL - Company profit before taxes, interest and amortization|Earnings per share for the last twelve months Castle Biosciences|CSTL - Earnings per share for the last twelve months|Quarterly EPS earnings growth castlebiosciences.com|CSTL - Earnings per share growth rate in current year|Expected earnings per share growth for next year Castle Biosciences
Comprehensive company analysis:Castle Biosciences Corp CSTL
Manufactured products of Castle Biosciences, Inc.

Castle Biosciences dominance in oncology diagnostics, driven by patent-protected tests, makes the EV/EBITDA multiple dynamics of this capital-intensive business a key indicator of its market expansion resilience. This metric relates the total enterprise value, including debt, to operating profit, determining the business's ability to withstand rising costs and inflationary pressure, which allows investors to assess the risk of capital freeze amid revenue volatility.

Analysis of competing companies

EV/EBITDA Multiple CAI (Caris)|EV/EBITDA Multiple Guardant Corp GH|VCYT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CELC (celcuity.com) - Enterprise Value to Operating Income Before Depreciation|GRAL: EV/EBITDA Multiple|Myriad Genetics Inc (MYGN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Burning Rock Biotech Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization VNRX|Enterprise Value to EBITDA Ratio BDSX (Biodesix, Inc.)|PRPO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Check-Cap CHEK|Total Company Value to Operating Income Before Depreciation Ratio mainzbiomed.com (MYNZ)|OncoCyte Corp. - EV/EBITDA Multiple